APA (7th ed.) Citation

Yuya Tsurutani, M., Masao Omura, M., Yoko Matsuzawa, M., Jun Saito, M., Mariko Higa, M., Matsuo Taniyama, M., & Tetsuo Nishikawa, M. (2017). Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Atherosclerosis, β-Cell Function, and Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Who are Treatment Naïve or Poorly Responsive to Antidiabetes Agents: A Multicenter, Prospective Observational, Uncontrolled Study. Elsevier.

Chicago Style (17th ed.) Citation

Yuya Tsurutani, MD, MD Masao Omura, MD Yoko Matsuzawa, MD Jun Saito, MD Mariko Higa, MD Matsuo Taniyama, and MD Tetsuo Nishikawa. Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Atherosclerosis, β-Cell Function, and Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Who Are Treatment Naïve or Poorly Responsive to Antidiabetes Agents: A Multicenter, Prospective Observational, Uncontrolled Study. Elsevier, 2017.

MLA (9th ed.) Citation

Yuya Tsurutani, MD, et al. Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Atherosclerosis, β-Cell Function, and Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Who Are Treatment Naïve or Poorly Responsive to Antidiabetes Agents: A Multicenter, Prospective Observational, Uncontrolled Study. Elsevier, 2017.